ALK-Abelló A/S (ALK-B.CO)
| Previous Close | 157.20 |
| Open | 157.40 |
| Bid | 158.60 x 0 |
| Ask | 158.30 x 0 |
| Day's Range | 156.10 - 159.90 |
| 52 Week Range | 69.90 - 159.90 |
| Volume | |
| Avg. Volume | 305,992 |
| Market Cap | 35.103B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 61.24 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 16, 2017 |
| 1y Target Est | N/A |
- GlobeNewswire
ALK upgrades its full-year revenue and earnings outlook
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder of the year. Revenue is now expected to grow by 12-15% in local currencies (prev.: 10-13%).The EBIT margin is now expected to improve to 18-20% (prev.: 17-19%) vs. 14% in 2023. The full-year revenue outlook has been upgraded primarily to reflect a continued strong momentum in tablet sales, impro
- GlobeNewswire
ALK provides update on regulatory process for the house dust mite allergy tablet in China
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in China. ALK will continue to work with the authorities to obtain regulatory approval of the HDM tablet in China, which may involve establishing additional clinical data in Chinese patients. The delay in the regulatory approval process does not impact ALK’s financial guidance for 2024, or its ability t
- GlobeNewswire
ALK launches new growth strategy and 2028 financial ambitions
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position in food allergy and anaphylaxis, as well as pursuing new innovations to address adjacent allergic conditions with high unmet needs. The strategy targets average revenue growth of minimum 10% in local currencies (5-year CAGR) until 2
